Elan Board Rejects Royalty Pharma Revised Tender Offer

Elan Corp.’s board unanimously rejected Royalty Pharma’s takeover offer days after it was raised to $6.7 billion, the second increase in its attempt to take over the Irish biotechnology company.

The latest offer “continues to grossly undervalue” Elan, the Dublin-based company said in a statement today. The board recommended that shareholders take no action on the offer and that they vote in favor of the four transactions previously announced by Elan when the June 17 shareholder meeting takes place.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.